Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for central venous catheter thrombosis in children
IRCT20231021059793N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rivaroxaban in Phlebothrombosis and catheter-related thrombosis (CRT), sponsored by Tehran University of Medical Sciences. Primary endpoints: Efficacy of rivaroxaban and Adverse effects of rivaroxaban. Started Mar 2024; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Phlebothrombosiscatheter-related thrombosis (CRT)
Beyond the preview
Go deeper on IRCT20231021059793N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231021059793N1.